BLUE Overview
Upcoming Projects (BLUE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BLUE)
-
Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape.
Tickers: BLUE, GBT
Executed On: Dec 14, 2018 at 10:00 AM EST -
A 4th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 11, 2018 at 04:00 PM EDT -
A 3rd View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 02, 2018 at 03:00 PM EDT -
A 2nd Look: Discussing this week's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 29, 2018 at 01:00 PM EDT -
FLASH CALL: Discussing this morning's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 27, 2018 at 04:00 PM EDT -
Discussing the latest GBT Sickle Cell Trial for Voxelotor (Previously GBT440) and its market potential
Tickers: GBT, BLUE
Executed On: Apr 25, 2018 at 01:00 PM EDT -
Analyzing the Previously Released Data on Mast Therapeutics' (MSTX) Vepoloxamer in Sickle Cell Disease and What It Can Tell Us About The Drug's Chance For Success In The Phase 3 EPIC Trial (Interview 1 of 3)
Tickers: MSTX, PFE, BLUE
Executed On: May 03, 2016 at 10:30 AM EDT -
Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank. ForceRank is being called "Fanduel For Stocks" and is already live for real money.
Tickers: FORCERANK, BIIB, CELG, ALNY, BLUE, KITE, estimize
Executed On: Apr 07, 2016 at 03:00 PM EDT
Free Project
Upcoming & Overdue Catalysts (BLUE)
-
Bluebird Bio (BLUE) to complete Phase 2/3 Study of Hematopoietic Stem Cells Transduced with Lenti-D Lentiviral Vector for the treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD) in second half of 2018
Ticker: BLUE
Future Window: Aug 01, 2018 - Nov 01, 2018
Overdue
Occurred Catalysts (BLUE)
-
Bluebird Bio (BLUE) to finish Phase 1/2 study of LentiGlobin® BB305 in Beta-Thalassemia Major Subjects in September 2017
Ticker: BLUE
Occurred on: Dec 10, 2017 -
Phase 1/2 trial updated data of LentiGlobin for β-Thalassemia and Sickle Disease expected at ASH December 2016
Ticker: BLUE
Occurred on: Dec 05, 2016 -
BlueBird Bio's (BLUE) LentiGlobin for Transfusion-Dependent Beta Thalassemia Granted PRIME Status by EMA
Ticker: BLUE
Occurred on: Sep 21, 2016 -
Bluebird Bio (BLUE) CFO to resign, replaced by COO
Ticker: BLUE
Occurred on: Mar 18, 2016
Strategic Initiatives (BLUE)
-
Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Ticker: BLUE
Announcement Date: Dec 07, 2017
